Resveratrol - CAS:501-36-0

您当前的位置：

Resveratrol (Synonyms:白藜芦醇; trans-Resveratrol; SRT501)

目录号 : KM13291 CAS No. : 501-36-0 纯度 : 98%

产品说明书产品使用指南

Resveratrol (trans-Resveratrol; SRT501) 是一种天然多酚，具有抗氧化，抗炎，保护心脏和抗癌的特性。它的靶点广泛，如 mTOR、JAK、β-amyloid、Adenylyl cyclase、IKKβ、DNA polymerase。Resveratrol 也是一种特异性的 SIRT1 活化剂。Resveratrol 是有效的孕烷 X 受体 (PXR) 抑制剂。Resveratrol 是一种 Nrf2 激活剂，在小鼠模型中可以改善衰老相关的进行性肾损伤。Resveratrol 作用于内皮细胞促进 NO 产生。

规格	价格	是否有货
200mg		In-stock
500mg		In-stock
1g	询价	In-stock
5g	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Tylvalosin In-stock
AMOZ In-stock
Nalidixic acid sodium salt In-stock
Amorolfine HCL In-stock
Ormetoprim In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.

体外研究

Resveratrol (trans-Resveratrol; SRT501) is one of the numerous polyphenolic compounds found in several vegetal sources In the vast majority of cases, Resveratrol displays inhibitory/activatory effects in the micromolar range, which is potentially attainable pharmacologically, although targets with affinities in the nanomolar range have also been reported.
MCF-7 cells are plated in DME-F12 medium supplemented with 5% FBS in the presence of increasing concentrations of Resveratrol. Control cells are treated with the same volume of vehicle only (0.1% ethanol). Resveratrol inhibits the growth of MCF-7 cells in a dose-dependent fashion. Addition of 10 μM Resveratrol results in an 82% inhibition of MCF-7 cell growth after 6 days while at 1 μM, only a 10% inhibition is observed. The cells treated with 10 μM Resveratrol have a doubling time of 60 hr whereas control cells doubled every 30 hr. Trypan blue exclusion assay shows that at concentrations of 10 μM or lower, Resveratrol does not affect cell viability (90% viable cells) whereas at 100 μM, only 50% of the cells are viable after 6 days of Resveratrol treatment. Moreover, MCF-7 cells do not undergo apoptosis after incubation with Resveratrol at concentration of 10 μM as determined by ApoAlert Annexin V Apoptosis kit.
Resveratrol increases the production of nitric oxide (NO) in endothelial cells by upregulating the expression of endothelial NO synthase (eNOS), stimulating eNOS enzymatic activity, and preventing eNOS uncoupling.

体内研究

The average tumor volume is reduced by treatment with Resveratrol (trans-Resveratrol; SRT501) at a dose of 50 mg/kg body weight (195.5±124.8 mm; P<0.05) or 100 mg/kg body weight (81.7±70.5 mm; P<0.001) compare with the vehicle-treated animals (315±94 mm). There is a good correlation between the tumor volume and the tumor mass.

分子式

C₁₄H₁₂O₃

分子量

228.24

CAS号

501-36-0

中文名称

白藜芦醇；茋三酚；芪三酚

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (438.14 mM; Need ultrasonic)

Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.3814 mL	21.9068 mL	43.8135 mL
5 mM	0.8763 mL	4.3814 mL	8.7627 mL
10 mM	0.4381 mL	2.1907 mL	4.3814 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 16.67 mg/mL (73.04 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 50% PEG300 50% saline
Solubility: 12.5 mg/mL (54.77 mM); Suspended solution; Need ultrasonic
3.

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% saline
Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic

此方案可获得 5 mg/mL (21.91 mM) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
4.

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in saline)
Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic

此方案可获得 5 mg/mL (21.91 mM) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
5.

请依序添加每种溶剂： 10% EtOH 90% corn oil
Solubility: ≥ 5 mg/mL (21.91 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (21.91 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中，混合均匀。
6.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.95 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
7.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.95 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
8.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.95 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
9.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
10.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution